M&A: Alcon acquires BELKIN Vision for $81 million

Alcon (SIX/NYSE: ALC), a leading company in eye care, has announced the completion of its $81 million acquisition of BELKIN Vision. This strategic move aims to bolster Alcon’s presence in the glaucoma treatment sector. By acquiring BELKIN Vision’s innovative Direct Selective Laser Trabeculoplasty (DSLT) technology, Alcon significantly enhances its range of treatment options for glaucoma patients. DSLT is a minimally invasive procedure that offers physicians a new tool to potentially improve patient care and outcomes.

"As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, President, Global Surgical Franchise, Alcon. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet glaucoma needs, " he added.

Alcon’s acquisition agreement includes an initial $65 million cash payment, with the potential for an additional $385 million contingent on achieving specific sales milestones. This deal grants Alcon access to BELKIN Vision’s pioneering DSLT technology, which will be seamlessly integrated into Alcon’s established Vision Suite ecosystem. This integration underscores Alcon’s commitment to providing comprehensive glaucoma management solutions, including ongoing training and best-in-class service for its customers.

With plans to enter the US market, Alcon’s acquisition of BELKIN Vision positions the company as a leader in delivering advanced and effective solutions for glaucoma management, further cementing its reputation in the eye care industry.